- -

Experience with fulvestrant acetate in castration-resistant prostate cancer patients

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Experience with fulvestrant acetate in castration-resistant prostate cancer patients

Mostrar el registro completo del ítem

Gasent Blesa, JM.; Alberola Candel, V.; Giner Marco, V.; Giner-Bosch, V.; Provencio Pulla, M.; Laforga Canales, JB. (2010). Experience with fulvestrant acetate in castration-resistant prostate cancer patients. Annals of Oncology. 21(5):1131-1132. doi:10.1093/annonc/mdq010

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/98412

Ficheros en el ítem

Metadatos del ítem

Título: Experience with fulvestrant acetate in castration-resistant prostate cancer patients
Autor: Gasent Blesa, J. M. Alberola Candel, V. Giner Marco, V. Giner-Bosch, Vicent Provencio Pulla, M. Laforga Canales, J. B.
Entidad UPV: Universitat Politècnica de València. Departamento de Estadística e Investigación Operativa Aplicadas y Calidad - Departament d'Estadística i Investigació Operativa Aplicades i Qualitat
Fecha difusión:
Derechos de uso: Reserva de todos los derechos
Fuente:
Annals of Oncology. (issn: 0923-7534 )
DOI: 10.1093/annonc/mdq010
Editorial:
Oxford University Press
Versión del editor: https://doi.org/10.1093/annonc/mdq010
Tipo: Artículo

References

Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990). Inhibition of estrogen receptor-DNA binding by the «pure» antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences, 87(17), 6883-6887. doi:10.1073/pnas.87.17.6883

Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992). Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences, 89(9), 4037-4041. doi:10.1073/pnas.89.9.4037

Leav, I., Lau, K.-M., Adams, J. Y., McNeal, J. E., Taplin, M.-E., Wang, J., … Ho, S.-M. (2001). Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma. The American Journal of Pathology, 159(1), 79-92. doi:10.1016/s0002-9440(10)61676-8 [+]
Fawell, S. E., White, R., Hoare, S., Sydenham, M., Page, M., & Parker, M. G. (1990). Inhibition of estrogen receptor-DNA binding by the «pure» antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proceedings of the National Academy of Sciences, 87(17), 6883-6887. doi:10.1073/pnas.87.17.6883

Dauvois, S., Danielian, P. S., White, R., & Parker, M. G. (1992). Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proceedings of the National Academy of Sciences, 89(9), 4037-4041. doi:10.1073/pnas.89.9.4037

Leav, I., Lau, K.-M., Adams, J. Y., McNeal, J. E., Taplin, M.-E., Wang, J., … Ho, S.-M. (2001). Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma. The American Journal of Pathology, 159(1), 79-92. doi:10.1016/s0002-9440(10)61676-8

Bhattacharyya, R. S. (2006). Fulvestrant (ICI 182,780) down-regulates androgen receptor expression and diminishes androgenic responses in LNCaP human prostate cancer cells. Molecular Cancer Therapeutics, 5(6), 1539-1549. doi:10.1158/1535-7163.mct-06-0065

Galsky, M. D., Simon, K., Sonpavde, G., Hutson, T. E., Fleming, M., Kondagunta, G. V., & Berry, W. (2009). Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Annals of Oncology, 20(5), 965-966. doi:10.1093/annonc/mdp199

Serrate, C., Loriot, Y., De La Motte Rouge, T., Gross-Goupil, M., Massard, C., Escudier, B., … Fizazi, K. (2009). Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer. Annals of Oncology, 20(5), 965-965. doi:10.1093/annonc/mdp112

Chadha, M. K., Ashraf, U., Lawrence, D., Tian, L., Levine, E., Silliman, C., … Trump, D. L. (2008). Phase II study of fulvestrant (faslodex®) in castration resistant prostate cancer. The Prostate, 68(13), 1461-1466. doi:10.1002/pros.20813

[-]

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem